<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/779CA70F-9F69-4C4D-B3F7-09DA4FF63A94"><gtr:id>779CA70F-9F69-4C4D-B3F7-09DA4FF63A94</gtr:id><gtr:name>Apitope</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CE3FD7E0-3664-4B1E-9B3A-B30C8F846C6C"><gtr:id>CE3FD7E0-3664-4B1E-9B3A-B30C8F846C6C</gtr:id><gtr:name>Peninsula College Of Medecine and Dentistry Foundation</gtr:name><gtr:address><gtr:line1>Harscombe House 1 Darklake View
Estover</gtr:line1><gtr:city>Plymouth</gtr:city><gtr:postCode>PL6 7TL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Human Genetics</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/779CA70F-9F69-4C4D-B3F7-09DA4FF63A94"><gtr:id>779CA70F-9F69-4C4D-B3F7-09DA4FF63A94</gtr:id><gtr:name>Apitope</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CE3FD7E0-3664-4B1E-9B3A-B30C8F846C6C"><gtr:id>CE3FD7E0-3664-4B1E-9B3A-B30C8F846C6C</gtr:id><gtr:name>Peninsula College Of Medecine and Dentistry Foundation</gtr:name><gtr:address><gtr:line1>Harscombe House 1 Darklake View
Estover</gtr:line1><gtr:city>Plymouth</gtr:city><gtr:postCode>PL6 7TL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0D664919-39C4-4638-AB75-E82A428AB7F8"><gtr:id>0D664919-39C4-4638-AB75-E82A428AB7F8</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Pearce</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/57A37958-62F0-4123-94F1-B401A3343848"><gtr:id>57A37958-62F0-4123-94F1-B401A3343848</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Dudley</gtr:otherNames><gtr:surname>Isaacs</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0701632"><gtr:id>19283C9C-7DF5-475B-834A-28F3C9227A36</gtr:id><gtr:title>Immunotherapeutic rescue of steroidogenic function in autoimmune Addison's disease: Pilot Study</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701632</gtr:grantReference><gtr:abstractText>Autoimmune Addison`s disease is a chronic disease caused by the body`s immune system attacking and eventually destroying the adrenal glands. This causes deficiency of certain steroid hormones that are essential for life and wellbeing, which the healthy adrenal glands normally produce. The current approach to treating Addison`s disease is simply to replace the missing adrenal steroid hormones using tablets. This makes people feel better, but often not fully back to normal and leaves them chronically dependent upon steroid medications (2 or 3 doses daily), with several long-term side effects, as well as a reduced life-expectancy. 

We plan a radical new approach to treatment of Addison`s disease, which is to try to switch off the immune system, so the attack on the adrenal glands ceases. We will use a safe but powerful treatment called rituximab that removes a certain type of immune cell, called the B lymphocyte, from the bloodstream and tissues. This treatment has been used on more than a million people with blood conditions over the last 10 years, and is given as two 4-hour infusions, 14 days apart. The results of rituximab therapy in several other autoimmune disease show great promise, with substantial amelioration of disease. As adrenal tissue is already known to have a great capacity for regeneration, it is highly likely that the remaining (not destroyed) adrenal cells will regenerate, restoring the secretion of the vital steroid hormones to normal, once the immune attack has gone. The body naturally makes an adrenal gland stimulating hormone, ACTH-adrenocorticotropic hormone, when adrenal secretions are deficient or below the necessary levels. People with Addison`s have very high levels of ACTH, and this would cause the regeneration of the adrenal glands once the immune attack has been removed. This strategy could lead to a permanent cure of autoimmune Addison s disease, for the first time.</gtr:abstractText><gtr:technicalSummary>Autoimmune Addison`s disease (AAD) is a rare and debilitating disease in which an autoimmune attack progressively destroys the adrenal cortex. Untreated it is universally fatal and treated people are absolutely dependent upon steroid medications lifelong, with a consequent excess in morbidity and mortality. Treatment is supportive only, with no attempt to modify the natural history of the disease process. A key feature of AAD is that in recent years it is often diagnosed at a stage when subjects have some residual adrenal steroidogenic capacity. As adrenal tissue is highly plastic, this residual steroidogenic tissue may be able to regenerate and restore adrenal functional to normality, if the autoimmune process can be arrested.
We will perform a pilot study of B cell depletion therapy (rituximab) to salvage adrenal steroidogenic capacity in six subjects with autoimmune Addison`s disease. During the first twelve weeks of treatment, additional glucocorticoid therapy will be given to ensure wellbeing and to rest the steroidogenic apparatus that is the target of the autoimmune attack. Response to treatment will be judged by gold-standard endocrine indices of adrenocortical function and autoantibody assays. We believe that this therapy may have the potential to ameliorate the autoimmune attack against adrenal cells, allowing a state of immune tolerance to be restored with subsequent regeneration of adrenal steroidiogenic capacity.
If successful, this study would mark a sea-change in thinking about the therapeutic approach to autoimmune Addison`s disease. In addition to demonstrating proof of principle, it would also provide the key mechanistic insight that B cells have a central role in promulgation or maintenance of adrenal autoimmunity.</gtr:technicalSummary><gtr:fund><gtr:end>2011-04-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>149934</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Peninsula College of Medicine &amp; Dentistry</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Endocrinology</gtr:department><gtr:description>Second trial centre</gtr:description><gtr:id>A4ED7328-EF8E-4F87-AD7E-57242E4D4779</gtr:id><gtr:impact>Patient recruitment to the trial was enabled</gtr:impact><gtr:partnerContribution>Recruiting patients to study</gtr:partnerContribution><gtr:piContribution>A second trial site was opened at Exeter</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Apitope</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>APitope</gtr:description><gtr:id>38160DAD-7548-4BF2-ADB5-8FBB53BA0E1A</gtr:id><gtr:impact>A novel immunotherapeutic compound is in development. First in man study has started, led by me.</gtr:impact><gtr:partnerContribution>Provided expertise in therapeutic peptide design and immunological tolerance assays.</gtr:partnerContribution><gtr:piContribution>Provided clinical samples for development and testing of a novel therapeutic in vitro. Provided clinical expertise with trial design. First in man clinical trial now underway with first 2 'global' patients dosed at my centre.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Endocrinology, Diabetes and Metabolism</gtr:department><gtr:description>Steroid Metabolome</gtr:description><gtr:id>98B134A1-1E0E-46D7-92F9-F678B0C4D173</gtr:id><gtr:impact>Research paper in JCEM</gtr:impact><gtr:partnerContribution>Provided GC-MS/MS of urine steroid metabolome</gtr:partnerContribution><gtr:piContribution>Provided samples for analysis, and IP for the concept being examined</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>TED patient resource day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3B5A71FE-3CC1-490A-9CAE-346BB94AE713</gtr:id><gtr:impact>Prioritisation of importance of research questions to patients and public

A paper will be published outlining the outputs from the event.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Addison's disease self help group. Meeting October 8th Newcastle</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>7E1E1F52-ED40-4D51-9660-F71B9353333A</gtr:id><gtr:impact>30 patients with Addison's and their partners/ family attended for a seminar about managing their condition and the principles behind the research studies were discussed

NA</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>28000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concept (Newcastle University managed, MRC)</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Newcastle University</gtr:fundingOrg><gtr:id>8C6EEEB6-E57D-440A-B6CC-A55A9E4F3166</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>530000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developmental Clinical Studies</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J002526/1</gtr:fundingRef><gtr:id>E9CBE9EE-348C-4174-BEBA-8ADD298576D7</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>340000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Translational Stem Cell Research Committee (TSCRC) Grant</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G900001</gtr:fundingRef><gtr:id>BD9D599F-7AE3-41C6-8ADB-39BF2064F191</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EU Adrenal insufficiency guidelines</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>54AE780B-865F-4868-8008-EE9884BD1E61</gtr:id><gtr:impact>Standardised investiagtion and management of a rare condition across the EU.</gtr:impact><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Patients with new onset Addison's disease were treated with immunotherapy. One had a sustained remission, giving proof of principle that the disease is plastic at presentation in some cases and that disease-modifying therapies may have a role.</gtr:description><gtr:id>DE28A076-1714-4701-B109-31E678602CAF</gtr:id><gtr:impact>This study demonstrated for the first time that autoimmune Addison's disease is a potentially remediable state.</gtr:impact><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>RADS: rescue of addison's disease study</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>UKCRN 5143</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E9BD5F6F-7313-4FC8-BD91-FC114C6C3FD4"><gtr:id>E9BD5F6F-7313-4FC8-BD91-FC114C6C3FD4</gtr:id><gtr:title>The role of a nonsynonymous CD226 (DNAX-accessory molecule-1) variant (Gly 307Ser) in isolated Addison's disease and autoimmune polyendocrinopathy type 2 pathogenesis.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/035d0e4c4756ccd97aba54ac23cbeebc"><gtr:id>035d0e4c4756ccd97aba54ac23cbeebc</gtr:id><gtr:otherNames>Gan EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB95171A-1848-47B6-8C43-0DD4F9B2E8D4"><gtr:id>DB95171A-1848-47B6-8C43-0DD4F9B2E8D4</gtr:id><gtr:title>AIRE is not essential for the induction of human tolerogenic dendritic cells.</gtr:title><gtr:parentPublicationTitle>Autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44ffcf7282a73f1ed1a7a4f75f626ba1"><gtr:id>44ffcf7282a73f1ed1a7a4f75f626ba1</gtr:id><gtr:otherNames>Crossland KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0891-6934</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/012628B9-7FAA-4C82-868F-1C08638BFC08"><gtr:id>012628B9-7FAA-4C82-868F-1C08638BFC08</gtr:id><gtr:title>Saving lives of in-patients with adrenal insufficiency: implementation of an alert scheme within the Newcastle-upon-Tyne Hospitals e-Prescribing platform.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/40d4aefc449834f9c0aba834ea778607"><gtr:id>40d4aefc449834f9c0aba834ea778607</gtr:id><gtr:otherNames>Mitchell AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B90770AA-2507-4042-A333-978E4B61E8AB"><gtr:id>B90770AA-2507-4042-A333-978E4B61E8AB</gtr:id><gtr:title>Linkage Analysis in Autoimmune Addison's Disease: NFATC1 as a Potential Novel Susceptibility Locus.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/40d4aefc449834f9c0aba834ea778607"><gtr:id>40d4aefc449834f9c0aba834ea778607</gtr:id><gtr:otherNames>Mitchell AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C410EA10-0B87-4731-9166-53CB619B73E3"><gtr:id>C410EA10-0B87-4731-9166-53CB619B73E3</gtr:id><gtr:title>The role of functionally defective rare germline variants of sialic acid acetylesterase in autoimmune Addison's disease.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/035d0e4c4756ccd97aba54ac23cbeebc"><gtr:id>035d0e4c4756ccd97aba54ac23cbeebc</gtr:id><gtr:otherNames>Gan EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E37544CA-135B-4D05-BB97-EFB12D4CE0C0"><gtr:id>E37544CA-135B-4D05-BB97-EFB12D4CE0C0</gtr:id><gtr:title>Insufficient evidence to favour prednisolone over hydrocortisone in glucocorticoid replacement.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f78ce76102cae0546d0d6557520cfc67"><gtr:id>f78ce76102cae0546d0d6557520cfc67</gtr:id><gtr:otherNames>Pearce SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B49F8A12-C680-411C-AA7D-33008D608E9B"><gtr:id>B49F8A12-C680-411C-AA7D-33008D608E9B</gtr:id><gtr:title>Impact of Month of Birth on the Risk of Development of Autoimmune Addison's Disease.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b865d2d8238576275b62c4feb90ac66"><gtr:id>9b865d2d8238576275b62c4feb90ac66</gtr:id><gtr:otherNames>Pazderska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BE4E06C0-EBFF-4C46-AAE5-53011172477A"><gtr:id>BE4E06C0-EBFF-4C46-AAE5-53011172477A</gtr:id><gtr:title>Autoimmune Addison disease: pathophysiology and genetic complexity.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/40d4aefc449834f9c0aba834ea778607"><gtr:id>40d4aefc449834f9c0aba834ea778607</gtr:id><gtr:otherNames>Mitchell AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1759-5029</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C664FB16-1D9A-416A-A94E-7CCE2EE265CA"><gtr:id>C664FB16-1D9A-416A-A94E-7CCE2EE265CA</gtr:id><gtr:title>A Variant in the BACH2 Gene Is Associated With Susceptibility to Autoimmune Addison's Disease in Humans.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b865d2d8238576275b62c4feb90ac66"><gtr:id>9b865d2d8238576275b62c4feb90ac66</gtr:id><gtr:otherNames>Pazderska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2E0445D2-D680-4C4E-9F58-3446C2B86944"><gtr:id>2E0445D2-D680-4C4E-9F58-3446C2B86944</gtr:id><gtr:title>MANAGEMENT OF ENDOCRINE DISEASE: Regenerative therapies in autoimmune Addison's disease.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/035d0e4c4756ccd97aba54ac23cbeebc"><gtr:id>035d0e4c4756ccd97aba54ac23cbeebc</gtr:id><gtr:otherNames>Gan EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B26246FC-343A-4016-A6FA-2B8326D26538"><gtr:id>B26246FC-343A-4016-A6FA-2B8326D26538</gtr:id><gtr:title>CTLA-4 as a genetic determinant in autoimmune Addison's disease.</gtr:title><gtr:parentPublicationTitle>Genes and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9d8f9b1266e842b448d31a804555e684"><gtr:id>9d8f9b1266e842b448d31a804555e684</gtr:id><gtr:otherNames>Wolff AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1466-4879</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BAEF48AE-31D5-478D-9B2D-E654ABFD895A"><gtr:id>BAEF48AE-31D5-478D-9B2D-E654ABFD895A</gtr:id><gtr:title>Adrenal steroidogenesis after B lymphocyte depletion therapy in new-onset Addison's disease.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f78ce76102cae0546d0d6557520cfc67"><gtr:id>f78ce76102cae0546d0d6557520cfc67</gtr:id><gtr:otherNames>Pearce SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701632</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>